Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases - GACD)
HORIZON Research and Innovation Actions
Basic Information
- Identifier
- HORIZON-HLTH-2024-DISEASE-13-01
- Programme
- Tackling diseases (Single stage - 2024)
- Programme Period
- 2021 - 2027
- Status
- Closed (31094503)
- Opening Date
- April 25, 2024
- Deadline
- November 26, 2024
- Deadline Model
- single-stage
- Budget
- €20,000,000
- Min Grant Amount
- €3,000,000
- Max Grant Amount
- €4,000,000
- Expected Number of Grants
- 5
- Keywords
- HORIZON-HLTH-2024-DISEASE-13-01HORIZON-HLTH-2024-DISEASE-13Chronic diseasesClinical managementGlobal healthHealth careHealth inequalitiesHealth services, health care researchHealthcare systemHomecareIntegrated careMedical servicePatient carePublic health policies
Description
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to some of the following expected outcomes:
- Health care practitioners and providers in low- and middle-income countries (LMICs) and/or those in high-income countries (HICs) serving disadvantaged populations have access to and use specific guidelines to implement health interventions that improve the availability of effective, equitable, efficient, integrated, patient-centred, safe, and timely care and the overall quality of life for people living with multiple long-term conditions including non-communicable diseases (NCDs).
- Public health managers and authorities, including from other relevant sector (e. g., social, culture) have access to improved insights and evidence on how to decrease the fragmentation of care for patients living with multiple chronic conditions, and ensure continuity of care across all stages of disease progression. They use this knowledge to design policies to reduce health inequities.
- Adopting an implementation science approach to studying interventions for management of multiple long-term conditions in the context of NCDs, researchers, clinicians and authorities have an improved understanding how the proposed interventions could be adopted in LMICs and/or disadvantaged populations of HICs setting, taking into account specific social, political, economic and cultural contexts.
- Communities and local stakeholders and authorities are fully engaged in implementing and taking up interventions for management of multiple long-term conditions in the context of NCDs and thus contribute to deliver better health.
The European Commission is a member of the Global Alliance for Chronic Diseases (GACD)[1], an alliance of international funding agencies representing over 80% of the world’s public health research funding and the first collaboration of its kind to specifically address NCDs. The GACD supports implementation science to improve health outcomes. This topic is launched in concertation with the other GACD members and aligned with the 9th GACD call.
The topic is focused on implementation research for management of multiple long-term conditions in the context of NCDs (MLTC NCD) in LMICs and/or disadvantaged populations in HICs. Proposals should focus on implementation science around interventions that will generate evidence about when, for whom, and under what circumstances, patient-centred approaches can improve integrated care for patients with MLTC NCD.
MLTC NCD refers to the co-occurrence of multiple chronic conditions, at least one of which is an NCD. NCDs include for example cardiovascular diseases, chronic respiratory diseases, cancers, musculoskeletal disorders, diabetes, hypertension, haematological disorders, sleep disorders, and mental health disorders. The high prevalence of MLTC NCD is projected to rise with the ageing population and the increasing burden of NCDs. MLTC NCD has a profound impact on patients, and is associated with premature death, physical disability, substance abuse, poor quality of life, mental health issues, and financial difficulties from high costs of care. It is also associated with difficulties in adherence to and high rates of adverse effects from treatment with multiple medications. In addition, due to poor health and the complexity of managing their conditions, patients with MLTC NCD are high utilisers of health care systems, which is especially challenging in low-resourced contexts.
Addressing MLTC NCD demands a shift from fragmented models of care, which treat individual health issues separately as they occur, to a more holistic integrated care model that provides a whole person focus on health management[2]. The current evidence suggests that primary healthcare[3], integrated and coordinated care, patient-centred interventions, digital health technology, and optimised medication therapy are key to improved management of MLTC NCD. However, implementing patient-centred strategies for treating MLTC NCD remains challenging and largely unexplored in disadvantaged contexts, especially in LMICs. Adapting and scaling such models is critical to improving quality of life; reducing disability; reducing the burden of caretaking on (typically female) family members and reducing health system costs.
The proposed implementation research must focus on one or more evidence-based interventions (or complex interventions) known to promote integrated management of multiple long-term conditions, including NCDs. It should assess patient-centred interventions focused on patient management or self-management, or interventions that transform communities, clinical practice, and/or health systems. Applicants should justify the choice of intervention(s) and provide evidence of the intervention’s effectiveness, acceptability, feasibility, and potential for long-term health and other impacts. Ideally, evidence of the intervention’s real-world effectiveness should be supported by a well-conducted systematic review where available. As the evidence for how to manage MLTC NCD is still emerging, particularly in LMICs, a limited period of testing the effectiveness of an intervention that the applicant’s team has adapted for local implementation is therefore usually appropriate.
Applicants must explore the implementation of proposed intervention(s) for a selected study population(s) taking into account the unique social, political, economic, and cultural context(s) in which the study will take place. Applicants should justify why any adaptation will not compromise the known effectiveness of the selected intervention(s).
Proposals should address all of the following activities[4]:
- Provide a research plan using validated implementation research frameworks or hybrid design research;
- Have an appropriate strategy for measuring implementation research outcomes and real-world effectiveness outcomes and indicators;
- Specifically address health equity and the principles of Universal Health Coverage[5];
- Engage an appropriately expert and skilled research team which can ensure a suitable multidisciplinary approach and that demonstrates equitable partnership and shared leadership between HIC-LMIC, and/or non-Indigenous–Indigenous members of the project team and external stakeholders through a clear governance strategy;
- Provide a stakeholder engagement strategy with evidence of support/engagement from key stakeholders for delivering patient-centred care and a pathway to sustain the proposed intervention after the funding ends;
- Provide opportunities for implementation research capacity building for early career researchers and team members from lower resourced environments, such as LMICs or disadvantaged communities.
- Ensure meaningful involvement of early career team members, including at least one early career member as a co-investigator.
Applicants are also encouraged to follow a life course approach, adapting the intervention to one or more key life stage(s) critical for reducing the onset or progression of MLTC NCD, and to explore how to best implement digital technology interventions.
The study population may include patients with existing MLTC NCD, or existing NCDs (e.g., studies focusing on rolling out screening services for multiple NCDs). The study population may also include patients with chronic infectious disease(s) (e.g., studies that focus on integrating NCD management into an HIV or tuberculosis clinic) or a mixture of both.
The following are potential interventions or strategies that applicants may consider in their implementation plan (please note that this is not an exhaustive list):
- Strategies for improving MLTC NCD identification, stratification/staging, management, and/or monitoring such as investigating strategies for adapting and implementing the protocol(s) described in the WHO Package of Essential NCD Interventions (WHO PEN)[6] that address MLTC NCD management. For example, projects may focus on integrating NCD care into clinics that typically focus on the management of infectious diseases, such as HIV or tuberculosis clinics, or the integration of NCD care into maternal and child health clinics;
- Strategies to streamline and improve quality of care among individuals with MLTC NCD to reduce fragmentation of services, including task-sharing and/or the use of clinical decision-making tools (e.g., digital tools);
- Strategies and/or tools (e.g., digital tools) that optimise appropriate medication and (non-pharmacological) therapeutic prescribing, adherence, and/or reduced drug interactions/ adverse effects;
- Interventions that improve transitions through the health system, from community to primary to tertiary care and beyond, such as to home care or hospice;
- Health behavioural change interventions that target different risk factor clusters (e.g., exercise, nutrition, tobacco, alcohol and substance abuse).
The proposal’s primary outcome measures must be implementation research outcomes to assess MLTC NCD. With regard to MLTC NCD, applicants are encouraged to explore any combination of chronic conditions, including mental health disorders and sleep disorders. The specific combination of conditions should be justified using local or regional epidemiological data about their co-occurrence. Outcome measures should appropriately address implementation tackling MLTC NCD, and not focus on one condition. Proposals may also contain a strategy for measuring other secondary outcomes (or proxy outcomes) that demonstrate the intervention’s real-world effectiveness in the local context and target populations. Additionally, other health or non-health outcome measures, especially those identified as important by patient participants and/or critical for advancing Universal Health Coverage, are also welcome.
Poverty, racism, ethnic discrimination, and other inequities are directly associated with reduced potential for equitable access to quality care. Proposals should consider the social determinants of health and discuss their potential impact on the effective implementation of the intervention(s). If there is a focus on a particular population (e.g., gender, ethnicity), then the reason for this should be justified.
In order to promote health equity, proposals should aim to address differences in intervention access, uptake, and effectiveness in socially disadvantaged groups and develop strategies for reducing inequities. To facilitate this process at the data analysis stage, studies should be designed to address such differences. At a minimum, studies should capture sex and/or gender differences. If feasible, a plan for capturing intersectional impacts on health outcomes should be included in the analysis strategy.
This topic requires the effective contribution of social sciences and humanities (SSH) disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities.
For implementation research to have a strong likelihood of being taken up into policy or practice and informing the scale up of effective interventions, it is vital that project teams engage the appropriate stakeholders. Proposals should present a strategy to include the relevant decision makers such as policymakers, ministry officials, local authorities, non-governmental organisation leaders, community leaders as well as other stakeholders such as community groups, or other individuals or organizations involved in the implementation of the intervention, from the development to the implementation knowledge translation phase. It is also important to include stakeholders who can help sustain the project’s implementation, facilitate scale up, and use the knowledge generated from the project after the grant ends.
Stakeholders also include patients, their family members and carers. Their contributions should be nurtured through meaningful engagement from the outset, not only as participants in the research undertaken. Patient engagement throughout the research project is critical to developing patient-centred models of care.
All projects funded under this topic are strongly encouraged to participate in networking and joint activities, including internationally, as appropriate. These activities could, for example, involve the participation in joint workshops, the Annual Scientific Meetings of the GACD, the exchange of knowledge, the development and adoption of best practices, or joint communication activities. Therefore, proposals are expected to include a budget for such activities and may consider covering the costs of any other potential joint activities without the prerequisite to detail concrete joint activities at this stage. The details of these joint activities will be defined during the grant agreement preparation phase.
Applicants envisaging to include clinical studies should provide details of their clinical studies in the dedicated annex using the template provided in the submission system. See definition of clinical studies in the introduction to this work programme part.
[2] In keeping with the principles of Universal Health Coverage, the World Health Organization advocates that health systems move towards offering a continuum of quality NCD preventative, diagnostic, curative, rehabilitative, and palliative care services, that are available and accessible to all, independent of economic circumstances.
[3] https://www.who.int/news-room/fact-sheets/detail/primary-health-care
[4] The following types of projects will NOT be funded: i) proposals focused on primary prevention of NCDs or other chronic conditions; ii) proposals with the primary aim of informing the development and/or selection of an intervention for a given context, where the implementation component will be explored in a future project; iii) epidemiological cohorts; iv) etiological work, mechanistic, or epidemiological research, unless an essential component of a focused study to develop implementation research approaches; v) clinical trials, validation studies, or intervention efficacy studies for a new or established pharmacological agent or behavioural intervention.
[5] https://www.who.int/health-topics/universal-health-coverage
Destination & Scope
Calls for proposals under this destination are directed towards the Key Strategic Orientation KSO-D ‘Creating a more resilient, inclusive and democratic European society’ of Horizon Europe’s Strategic Plan 2021-2024. Research and innovation supported under this destination should contribute to the impact area ‘Good health and high-quality accessible healthcare’ and in particular to the following expected impact, set out in the Strategic Plan for the health cluster: ‘health care providers are able to better tackle and manage diseases (infectious diseases, including poverty-related and neglected diseases, non-communicable and rare diseases) and reduce the disease burden on patients effectively thanks to better understanding and treatment of diseases, more effective and innovative health technologies, better ability and preparedness to manage epidemic outbreaks and improved patient safety’. In addition, research and innovation supported under this destination could also contribute to the following impact areas: ‘A resilient EU prepared for emerging threats’, ‘Climate change mitigation and adaptation’, and ‘High quality digital services for all’.
Communicable and non-communicable diseases cause the greatest amounts of premature death and disability in the EU and worldwide. They pose a major health, societal and economic threat and burden. Many people are still suffering from these diseases and too often dying prematurely. Non-communicable diseases, including mental illnesses and neurodegenerative diseases, are responsible for up to 80% of EU health care costs[1]. These costs are spent on the treatment of such diseases that to a large extent are preventable. Furthermore, only around 3% of the health care budgets are currently spent on preventive measures although there is a huge potential for prevention. Infectious diseases, including emerging infectious diseases and infections resistant to antimicrobials, remain a major threat to public health in the EU but also to global health security. Deaths caused by antimicrobial resistance (AMR) could exceed 10 million per year worldwide according to some predictions[2].
To further advance, there is an urgent need for research and innovation to develop new preparedness and prevention measures, public health interventions, diagnostics, vaccines, therapies, alternatives to antimicrobials, as well as to improve existing preparedness and prevention strategies to create tangible impacts, taking into account sex/gender-related issues. This will require international cooperation to pool the best expertise and know-how available worldwide, to access world-class research infrastructures and to leverage critical scales of investments on priority needs through a better alignment with other funders of international cooperation in health research and innovation. The continuation of international partnerships and cooperation with international organisations is particularly needed to combat infectious diseases, to address antimicrobial resistances, to respond to major unmet medical needs for global health security, including the global burden of non-communicable diseases, and to strengthen patient safety.
In this work programme, destination 3 will focus on major societal challenges linked to the Commission’s political priorities such as the fight against cancer and other non-communicable diseases, better diagnosis and treatment of rare diseases, preparedness and response to and surveillance of health threats and epidemics, reduction of the number of antimicrobial-resistant infections, improving vaccination rates, demographic change, mental health and digital empowerment in health literacy. In particular, the topics under this destination will support activities aiming at: i) better understanding of diseases, their drivers and consequences, including pain and the causative links between health determinants and diseases, and better evidence-base for policymaking; ii) better methodologies and diagnostics that allow timely and accurate diagnosis, identification of personalised treatment options and assessment of health outcomes, including for patients with a rare disease; iii) development and validation of effective intervention for better surveillance, prevention, detection, treatment and crisis management of infectious disease threats; iv) innovative health technologies developed and tested in clinical practice, including personalised medicine approaches and use of digital tools to optimise clinical workflows; v) new and advanced therapies for non-communicable diseases, including rare diseases developed in particular for those without approved options, supported by strategies to make them affordable for the public payer; and vi) scientific evidence for improved/tailored policies and legal frameworks and to inform major policy initiatives at global level (e.g. WHO Framework Convention on Tobacco Control; UNEA Pollution Implementation Plan).
In view of increasing the impact of EU investments under Horizon Europe, the European Commission welcomes and supports cooperation between EU-funded projects to enable cross-fertilisation and other synergies. This could range from networking to joint activities such as the participation in joint workshops, the exchange of knowledge, the development and adoption of best practices, or joint communication activities. Opportunities for potential synergies exist between projects funded under the same topic but also between other projects funded under another topic, cluster or pillar of Horizon Europe (but also with ongoing projects funded under Horizon 2020). In particular, this could involve projects related to European health research infrastructures (under pillar I of Horizon Europe), the EIC strategic challenges on health and EIT-KIC Health (under pillar III of Horizon Europe), or in areas cutting across the health and other clusters (under pillar II of Horizon Europe). For instance, with cluster 3 “Civil security for society” such as on health security/emergencies (preparedness and response, medical countermeasures, epidemic outbreaks/pandemics, natural disasters and technological incidents, bioterrorism); with cluster 4 “Digital, Industry and Space” such as on decision-support systems or on geo-observation and monitoring (e.g. of disease vectors, epidemics); or with cluster 6 “Food, bioeconomy, natural resources, agriculture and environment” such as on health security and AMR (one-health: human/animal/plant/soil/water health). In addition, while focusing on civilian applications, there may be there may be synergies with actions conducted under the European Defence Fund, notably in the field of defence medical countermeasures.
Based on needs that emerged during the management of COVID-19, some research and innovation actions under Destination 3 should support the mission of the European Health Emergency and Response Authority (HERA) to strengthen Europe’s ability to prevent, detect, and rapidly respond to cross-border health emergencies by ensuring the availability and access to key medical countermeasures. Other actions should deliver relevant complementary inputs to the “Europe’s Beating Cancer Plan”[3] in order to cover the entire cancer care pathway, including prevention, early detection, diagnosis, treatment, cancer data monitoring, as well as quality of life of cancer patients and survivors. Furthermore, synergies and complementarities will be sought between Destination 3 and the implementation of the EU4Health Programme (2021-2027)[4]. These synergies and complementarities could be achieved, notably through mechanisms based on feedback loops, enabling on the one hand to identify policy needs that should be prioritised in research and innovation actions and facilitating on the other hand the implementation of research results into policy actions and clinical practice, thereby providing an integrated response across sectors and policy fields.
Expected impacts:
Proposals for topics under this destination should set out a credible pathway to contributing to tackling diseases and reducing disease burden, and more specifically to several of the following impacts:
- Health burden of diseases in the EU and worldwide is reduced through effective disease management, including through the development and integration of innovative diagnostic and therapeutic approaches, personalised medicine approaches, digital and other people-centred solutions for health care. In particular, patients are diagnosed early and accurately and receive effective, cost-efficient and affordable treatment, including patients with a rare disease, due to effective translation of research results into new diagnostic tools and therapies.
- Premature mortality from non-communicable diseases is reduced by one third (by 2030), mental health and well-being is promoted, and the voluntary targets of the WHO Global Action Plan for the Prevention and Control of NCDs 2013-2020 are attained (by 2025), with an immediate impact on the related disease burden (DALYs)[5],[6], [7].
- Health care systems benefit from strengthened research and innovation expertise, human capacities and know-how for combatting communicable and non-communicable diseases, including through international cooperation. In particular, they are better prepared to respond rapidly and effectively to health emergencies and are able to prevent and manage communicable diseases transmissions epidemics, including within healthcare settings.
- Citizens benefit from reduced (cross-border) health threat of epidemics and AMR pathogens, in the EU and worldwide[8], [9].
- Patients and citizens are knowledgeable of disease threats, involved and empowered to make and shape decisions for their health, and better adhere to knowledge-based disease management strategies and policies (especially for controlling outbreaks and emergencies).
The EU benefits from high visibility, leadership and standing in international fora on global health and global health security.
[1] Currently, around 50 million people in the EU are estimated to suffer from two or more chronic conditions, and most of these people are over 65. Every day, 22 500 people die in Europe from those diseases, counting of 87% of all deaths. They account for 550 000 premature deaths of people of working age with an estimated €115 billion economic loss per year (0.8% of GDP).
[2] AMR is estimated to be responsible for 25 000 deaths per year in the EU alone and 700 000 deaths per year globally. It has been estimated that AMR might cause more deaths than cancer by 2050.
[4] https://ec.europa.eu/health/funding/eu4health_en
[5] WHO Global Action Plan for the Prevention and Control of NCDs 2013-2020 (resolution WHA66.10), https://www.who.int/publications/i/item/9789241506236
[6] Including for instance the following voluntary targets (against the 2010 baseline): A 25% relative reduction in the overall mortality from cardiovascular diseases, cancer, diabetes, or chronic respiratory diseases; Halt the rise in diabetes and obesity; An 80% availability of the affordable basic technologies and essential medicines, including generics, required to treat major non-communicable diseases in both public and private facilities.
[7] Disability-adjusted life year (DALY) is a quantitative indicator of overall disease burden, expressed as the number of years lost due to ill-health, disability or early death.
[8] WHO global action plan on antimicrobial resistance, 2015
[9] EU One Health Action Plan against AMR, 2017
Eligibility & Conditions
General conditions
2. Eligible countries: described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.
3. Other eligibility conditions: described in Annex B of the Work Programme General Annexes.
4. Financial and operational capacity and exclusion: described in Annex C of the Work Programme General Annexes.
Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes.
The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 3 (Implementation). The cumulative threshold will be 12.
Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual.
Indicative timeline for evaluation and grant agreement: described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants: described in Annex G of the Work Programme General Annexes.
Specific conditions
7. Specific conditions: described in the specific topic of the Work Programme.
Documents
Call documents:
Standard application form (HE RIA, IA) - call-specific application form is available in the Submission System
Standard evaluation form (HE RIA, IA)
HE General MGA v1.0
Information on clinical studies (HE)
Additional documents:
HE Main Work Programme 2023–2024 – 1. General Introduction
HE Main Work Programme 2023–2024 – 4. Health
HE Main Work Programme 2023–2024 – 13. General Annexes
HE Programme Guide
HE Framework Programme and Rules for Participation Regulation 2021/695
HE Specific Programme Decision 2021/764
EU Financial Regulation
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual
Funding & Tenders Portal Terms and Conditions
Funding & Tenders Portal Privacy Statement
Support & Resources
Online Manual is your guide on the procedures from proposal submission to managing your grant.
Horizon Europe Programme Guide contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.
Funding & Tenders Portal FAQ – find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.
Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.
National Contact Points (NCPs) – get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (‘third-countries’).
Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.
IT Helpdesk – contact the Funding & Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.
European IPR Helpdesk assists you on intellectual property issues.
CEN-CENELEC Research Helpdesk and ETSI Research Helpdesk – the European Standards Organisations advise you how to tackle standardisation in your project proposal.
The European Charter for Researchers and the Code of Conduct for their recruitment – consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.
Partner Search Services help you find a partner organisation for your proposal.
Latest Updates
We recently informed the applicants about the evaluation results for their proposals.
- Number of proposals submitted (including proposals transferred from or to other calls): 75
- Number of inadmissible proposals: 0
- Number of ineligible proposals: 5
- Number of above-threshold proposals: 15
- Total budget requested for above-threshold proposals: EUR 59,583,763.00
- Number of proposals retained for funding: 5
- Number of proposals in the reserve list: 3
- Funding threshold: 14
- Number of proposals with scores lower or equal to 15 and higher or equal to 14: 8
- Number of proposals with scores lower than 14 and higher or equal to 13: 5
- Number of proposals with scores lower than 13 and higher or equal to 12: 2
Summary of observer’s report:
Observer report on the evaluation process of three different Horizon 2024 topics: HORIZON-HLTH-2024-DISEASE-12-01 (a COFUND action), HORIZON-HLTH-2024-DISEASE-13-01 (a RIA action), and HORIZON-HLTH-2024-CARE-14-01 (a PCP action). The report evaluates the efficiency, transparency, and challenges encountered during the proposal assessment process. The observer attended remote briefings, a range of central consensus meetings, all three final panel meetings and held a number of private discussions with experts during the central week. Depending on the complexity of a topic, proposals were assessed with 4 or 5 or 6 experts. For example, the HORIZON-HLTH-2024-DISEASE-12-01 COFUND action, where only one proposal was eligible, required a thorough evaluation by six experts. This proposal was noted for its length and complexity across diverse areas of expertise. Overall, all procedures were carried out in a transparent way and briefings given were very good and clear. The quality of the documentation provided to experts beforehand was high although its complexity may have been overwhelming. As mentioned above, the complexity of the topics impacted the length of consensus meetings. For example, the consensus meetings of HORIZON-HLTH-2024-CARE-14-01 PCP actions required lengthier discussions and longer time slots should be allocated to such evaluations in the future. To increase the quality of the evaluation, a new approach to calibration was introduced to the HORIZON-HLTH-DISEASE-13-01 (RIA) topic by having one proposal discussed by all experts in addition to regular calibration meetings. While this approach brings added value to the evaluation, it should be considered to further improve the set-up to enable proper engagement. The remote briefings given to the experts before the central week worked well. For on-site evaluation, some technical issues were quickly resolved, demonstrating efficiency in handling logistical challenges. All of the moderators, experts and recorders displayed impartiality and respected confidentiality. Conflicts of interest were solved with respect for the rules. All procedures complied with the relevant existing rules. Experts suggested the need for a clearer interpretation of the call text integrated into the checklist, to help prevent potential inconsistencies. Lastly, the report calls for revisiting the criteria used to prioritise proposals with equal scores above the threshold as, for example, the current method of using gender balance among the researchers in the consortium is unpopular.
For questions, please contact the Research Enquiry Service.
Call HORIZON-HLTH-2024-DISEASE-13 closed on 26 November 2024. 75 proposals were submitted under topic HORIZON-HLTH-2024-DISEASE-13-01.
Evaluation results are expected to be communicated in February 2025.